InvestSMART

Syntara Limited (ASX:SNT)

ALERT: Price-sensitive ASX Announcement for SNT
Current share price for SNT : $0.021 -0.007 (-25%)+
Announcement
Release
30 Apr 2026 10:50AM
Price at Release
$0.028
Full Release
download
Summary
Syntara Limited, listed on the ASX under the code SNT, is progressing with various drug studies and partnerships. The company's quarterly cash flow report, ending 31 March 2026, highlights a net cash usage from operating activities of $(1,689), receiving government grants and tax incentives of $1,750, and maintaining cash and cash equivalents of $8,858. The report also details payments to related parties and does not reflect any new financing facilities. Syntara continues to explore innovative drug solutions while managing its financial and operational activities effectively.
Key Points
  • Syntara Limited is advancing drug studies including a Phase 1a/b study with SNT-9465 for hypertrophic scars.
  • The company is collaborating with the University of Western Australia and Parkinson’s UK on various drug candidates.
  • It has sold two respiratory products, Bronchitol® and Aridol®, in October 2023.
  • Syntara is listed on the Australian Securities Exchange under the code SNT.
  • The quarterly cash flow report covers cash flows from operating, investing, and financing activities.
  • Net cash used in operating activities was reported at $(1,689) for the current quarter.
  • The company received government grants and tax incentives totaling $1,750 for the quarter.
  • Payments to related parties included Director fees and salaries.
  • Cash and cash equivalents at the end of the period were reported at $8,858.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.